-
Frontiers in Immunology 2022
Topics: Humans; Antibodies, Antinuclear; Lupus Erythematosus, Systemic; Disease Susceptibility
PubMed: 36591294
DOI: 10.3389/fimmu.2022.1118180 -
Clinical and Experimental Rheumatology 2019In the past years the peripheral nervous system (PNS) involvement in systemic lupus erythematosus (SLE) has received little attention despite its potential significant... (Review)
Review
In the past years the peripheral nervous system (PNS) involvement in systemic lupus erythematosus (SLE) has received little attention despite its potential significant impact. The true prevalence of PNS in SLE reported in studies is variable and strongly influenced by American College of Rheumatology (ACR) case definition that includes seven PNS manifestations (acute inflammatory demyelinating polyradiculoneuropathy, autonomic disorder, mononeuropathy, myasthenia gravis, cranial neuropathy, plexopathy and polyneuropathy). Other peripheral manifestations, such as chronic inflammatory demyelinating polyradiculoneuropathy and small fibre neuropathy, not included in the ACR nomenclature, have not been well characterised in SLE. The aim of this review is to focus on epidemiology, pathogenesis, diagnosis and clinical features of all possible different expressions of PNS involvement in SLE, with the final objective to profile the patient's clinical characteristics.
Topics: Humans; Lupus Erythematosus, Systemic; Peripheral Nervous System; Peripheral Nervous System Diseases
PubMed: 29846158
DOI: No ID Found -
Reumatologia Clinica 2019There are national and international clinical practice guidelines for systemic lupus erythematosus treatment. Nonetheless, most of them are not designed for the Mexican...
There are national and international clinical practice guidelines for systemic lupus erythematosus treatment. Nonetheless, most of them are not designed for the Mexican population or are devoted only to the treatment of certain disease manifestations, like lupus nephritis, or are designed for some physiological state like pregnancy. The Mexican College of Rheumatology aimed to create clinical practice guidelines that included the majority of the manifestations of systemic lupus erythematosus, and also incorporated guidelines in controversial situations like vaccination and the perioperative period. The present document introduces the «Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus» proposed by the Mexican College of Rheumatology, which could be useful mostly for non-rheumatologist physicians who need to treat patients with systemic lupus erythematosus without having the appropriate training in the field of rheumatology. In these guidelines, the reader will find recommendations on the management of general, articular, kidney, cardiovascular, pulmonary, neurological, hematologic and gastrointestinal manifestations, and recommendations on vaccination and treatment management during the perioperative period.
Topics: Anti-Inflammatory Agents; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mexico
PubMed: 29735288
DOI: 10.1016/j.reuma.2018.03.011 -
Journal of Immunology Research 2018Oral signs are frequently the first manifestation of autoimmune diseases. For this reason, dentists play an important role in the detection of emerging autoimmune... (Review)
Review
Oral signs are frequently the first manifestation of autoimmune diseases. For this reason, dentists play an important role in the detection of emerging autoimmune pathologies. Indeed, an early diagnosis can play a decisive role in improving the quality of treatment strategies as well as quality of life. This can be obtained thanks to specific knowledge of oral manifestations of autoimmune diseases. This review is aimed at describing oral presentations, diagnosis, and treatment strategies for systemic lupus erythematosus, Sjögren syndrome, pemphigus vulgaris, mucous membrane pemphigoid, and Behcet disease.
Topics: Autoimmune Diseases; Behcet Syndrome; Diagnosis, Oral; Female; Humans; Lupus Erythematosus, Systemic; Male; Mouth; Mouth Diseases; Pemphigoid, Benign Mucous Membrane; Pemphigus; Prognosis; Sjogren's Syndrome
PubMed: 29977929
DOI: 10.1155/2018/6061825 -
Current Rheumatology Reports Jan 2019The concept of cellular senescence has been evolving. Although originally proposed based on studies of serum-driven replication of cell lines in vitro, it is now clear... (Review)
Review
PURPOSE OF REVIEW
The concept of cellular senescence has been evolving. Although originally proposed based on studies of serum-driven replication of cell lines in vitro, it is now clear that cellular senescence occurs in vivo. It has also become clear that cellular senescence can be triggered by a number of stimuli such as radiation, chemotherapy, activation of oncogenes, metabolic derangements, and chronic inflammation.
RECENT FINDINGS
As we learn more about the mechanisms of cellular aging, it has become important to ask whether accelerated cellular senescence occurs in lupus and other systemic rheumatologic diseases. Accelerated cellular aging may be one explanation for some of the excess morbidity and mortality seen in lupus patients. If so, drugs targeting cellular senescence may provide new options for preventing long-term complications such as organ failure in systemic lupus erythematosus patients.
Topics: Cellular Senescence; Humans; Lupus Erythematosus, Systemic
PubMed: 30637490
DOI: 10.1007/s11926-019-0800-6 -
Clinical & Developmental Immunology 2012
Topics: Animals; Autoimmune Diseases; Humans; Lupus Erythematosus, Systemic
PubMed: 23049599
DOI: 10.1155/2012/437282 -
Clinical and Experimental Rheumatology May 2024Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical manifestations and a relapsing-remitting course. SLE pathogenesis is the... (Review)
Review
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical manifestations and a relapsing-remitting course. SLE pathogenesis is the result of complex interactions between ethnic, genetic, epigenetic, immunoregulatory, hormonal and environmental factors, and several aspects of these multifactorial connections are still unclear. Overall, for the disease development, an environmental trigger may induce immunological dysfunction in genetically predisposed individuals. This review aims to summarise the most relevant data on the impact of environmental factors on the incidence of SLE and on disease activity and damage in patients with an established diagnosis of SLE.
Topics: Humans; Lupus Erythematosus, Systemic; Risk Factors; Gene-Environment Interaction; Genetic Predisposition to Disease; Incidence; Environmental Exposure; Environment
PubMed: 38743446
DOI: 10.55563/clinexprheumatol/17vmqc -
Frontiers in Immunology 2023Emerging evidence suggests an increased prevalence of coronavirus disease 2019 (COVID-19) in patients with systemic lupus erythematosus (SLE), the prototype of...
OBJECTIVE
Emerging evidence suggests an increased prevalence of coronavirus disease 2019 (COVID-19) in patients with systemic lupus erythematosus (SLE), the prototype of autoimmune disease, compared to the general population. However, the conclusions were inconsistent, and the causal relationship between COVID-19 and SLE remains unknown.
METHODS
In this study, we aimed to evaluate the bidirectional causal relationship between COVID-19 and SLE using bidirectional Mendelian randomization (MR) analysis, including MR-Egger, weighted median, weighted mode, and the inverse variance weighting (IVW) method.
RESULTS
The results of IVW showed a negative effect of SLE on severe COVID-19 (OR = 0.962, = 0.040) and COVID-19 infection (OR = 0.988, = 0.025), which disappeared after Bonferroni correction. No causal effect of SLE on hospitalized COVID-19 was observed (OR = 0.983, = 0.148). In the reverse analysis, no causal effects of severe COVID-19 infection (OR = 1.045, = 0.664), hospitalized COVID-19 (OR = 0.872, = 0.109), and COVID-19 infection (OR = 0.943, = 0.811) on SLE were found.
CONCLUSION
The findings of our bidirectional causal inference analysis did not support a genetically predicted causal relationship between SLE and COVID-19; thus, their association observed in previous observational studies may have been caused by confounding factors.
Topics: Humans; COVID-19; Lupus Erythematosus, Systemic; Autoimmune Diseases; Causality; Mendelian Randomization Analysis
PubMed: 37275906
DOI: 10.3389/fimmu.2023.1183570 -
Current Opinion in Rheumatology Sep 2015Systemic lupus erythematosus (SLE) is often preceded by immune dysregulation and clinical manifestations below the threshold for SLE classification. This review... (Review)
Review
PURPOSE OF REVIEW
Systemic lupus erythematosus (SLE) is often preceded by immune dysregulation and clinical manifestations below the threshold for SLE classification. This review discusses current and evolving concepts about the preclassification period of SLE, including clinical and mechanistic observations, and potential avenues for early identification and intervention.
RECENT FINDINGS
Although incomplete lupus erythematosus (ILE) involves fewer clinical manifestations than SLE, ILE patients can suffer organ damage and early mortality. Common clinical features in ILE include antinuclear antibody seropositivity, polyarthritis, immunologic manifestations, and hematological disorders. Despite having lower disease activity and damage scores than SLE patients, ILE patients may develop pulmonary arterial hypertension, or renal, neurological, or peripheral vascular damage. The recently proposed Systemic Lupus International Collaborating Clinics SLE classification criteria could shift the period considered 'preclinical SLE'. Murine studies suggest that the balance of T-helper/T-regulatory cells, peroxisome proliferator-activated receptor γ activity, and plasmacytoid dendritic cell pathways may be valuable targets for early intervention.
SUMMARY
Advances in our understanding of early SLE, including stages before clinical features are fully developed, will improve our ability to identify individuals at high risk of classification for potential prevention trials, provide necessary information to improve diagnostic testing, and perhaps identify novel targets for directed therapeutics in clinical SLE.
Topics: Early Diagnosis; Humans; Lupus Erythematosus, Systemic
PubMed: 26125103
DOI: 10.1097/BOR.0000000000000199 -
Clinical & Developmental Immunology 2012
Topics: Humans; Lupus Erythematosus, Systemic; Polymorphism, Genetic
PubMed: 22844327
DOI: 10.1155/2012/926931